Trimetazidine, Administered at the Onset of Reperfusion, Ameliorates Myocardial Dysfunction and Injury by Activation of p38 Mitogen-Activated Protein Kinase and Akt Signaling

Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine; TMZ] is an anti-ischemic cardiac drug; however, its efficacy and mechanism of cardioprotection upon reperfusion are largely unknown. The objective of this study was to determine whether TMZ, given before reperfusion, could attenuate myocardial rep...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Khan, Mahmood, Meduru, Sarath, Mostafa, Mahmoud, Khan, Saniya, Hideg, Kàlmàn, Kuppusamy, Periannan
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society for Pharmacology and Experimental Therapeutics 2010
Témata:
Cardiovascular
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2872960/
https://ncbi.nlm.nih.gov/pubmed/20167841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.109.165175
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky